Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

Total Net Revenue of $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48

CORONA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2008.

Second Quarter 2008 Results

Net revenue for the second quarter 2008 was $622.6 million and net income was $60.3 million, or $0.53 per diluted share. Net income for the second quarter 2008 included a gain related to a milestone payment and charges related to the Company's Global Supply Chain Initiative. Excluding special items as detailed in the reconciliation table below, adjusted net income for the second quarter was $54.6 million, or $0.48 per diluted share. Adjusted EBITDA for the second quarter 2008 was $137.5 million and cash flow from operations was $99.6 million. Cash and marketable securities were $278.2 million as of June 30, 2008.

"We are pleased with the financial results we delivered this quarter, driven by a strong performance in our Brand division which posted more than $100 million in product sales, a first in recent years," stated Paul Bisaro, Watson's President and Chief Executive Officer. "Our pipeline products oxybutynin topical gel for overactive bladder and silodosin for BPH were well received at data presentations at the recent American Urological Association meeting. Additionally, the FDA accepted our New Drug Application for our topical oxybutynin gel product and we successfully launched MixJect(TM), our new delivery system for Trelstar(R)."

"We continue to make progress on our near and long term strategic goals in the Generics Division, as evidenced by the recent product approvals and launches out of our
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DIEGO , March 3, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... Global Healthcare Conference in Miami.   The ... 10:15am ET (7:15am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:3/3/2015)... 2015  Regenicin, Inc. (OTC Bulletin Board: ... of and commercialization of regenerative cell therapies to restore ... that it has received the final payment to conclude ... (OTC Bulletin Board: AMBS ). ... final payments due to Regenicin in the amount of ...
(Date:3/3/2015)... , March 3, 2015  Thingee Corporation, a ... be delivering a presentation entitled, "Technology Adoption: Making Reps, ... Thriving through Innovations and Technology ,  in ... 11 to 13, 2015. Audiences looking to learn how ... will want to be in the audience for the ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Genedata, ... drug discovery and life science research, today announced ... (TM) enterprise platform for use at Pfizer biopharma ... Europe. Genedata is supporting Pfizer’s global deployment and ... (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... INTRODUCTION , ... which hydrolyze β -lactam antibiotics. The majority of β -lactamases produced ... to combating the serine active site β -lactamases is the use ... a β -lactam antibiotic 4 . , There is also a ...
... McGown, Ph.D. and Anna Lam, B.S., ... Molecular Devices Corporation, 8/99 , , INTRODUCTION ... use synthetic chromogenic or flu-orogenic peptide substrates. Enzyme selectivity is ... catalytic site of a particular enzyme. The chromophore or fluorophore ...
... Vronique Brechler, David Handfield, Martin Boissonneault, Esther Tremblay, ... Introduction , ... led to an unprecedented increase in both the number of compounds ... automated liquid handling and microplate assay systems has helped to meet ...
Cached Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 2Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 3Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 4Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 5Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 6Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 2Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 3Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 4Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 5
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... book titles to real estate developments, it,s easier to find ... it. That,s why a Kansas State University geographer is ... who might be trying to work toward it. Her goal ... have to make decisions about what to sustain with the ...
... WASHINGTONThe Wilson Center,s Synthetic Biology project recently ... One will support a Transatlantic Exploratory Workshop on ... and Policy, and the other will support research ... explore emerging issues in synthetic biology. The ...
... Ariz. (Sept. 22, 2009) TGen Clinical Research Services ... clinical trial for a drug designed to combat adrenocortical ... the adrenal glands. TCRS is a strategic alliance ... Healthcare. Other than surgery, the only treatment for ...
Cached Biology News:K-State geographer working to clarify what sustainability really means to rural decision-makers 2Revolutionary drug could be new hope for adrenal cancer patients 2Revolutionary drug could be new hope for adrenal cancer patients 3
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
ANTI MYCOBACTERIUM TUBERCULOSIS...
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: